2014 Vascular Dementias Therapeutics Clinical Trials Market
MarketOptimizer.org adds report “Vascular Dementias Global Clinical Trials Review, H2, 2014” to its store.
Vascular dementia or "multi-infarct dementia" is dementia caused by problems in the supply of blood to the brain, typically by a series of minor strokes. Vascular dementia is the second most common form of dementia after Alzheimer's disease (AD) in older adults. Multi-infarct dementia (MID) is thought to be irreversible and it is caused by a number of small strokes or sometimes a large stroke preceded or followed by other smaller strokes. The term refers to a group of syndromes caused by different mechanisms all resulting in vascular lesions in the brain. Early detection and accurate diagnosis are important, as vascular dementia is at least partially preventable.
“Vascular Dementias Global Clinical Trials Review, H2, 2014″ provides data on the Vascular Dementias clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vascular Dementias. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Vascular Dementias. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Complete report available @ http://www.marketoptimizer.org/vascular-dementias-global-clinical-trials-review-h2-2014.html .
Scope
• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by
Vascular dementia or "multi-infarct dementia" is dementia caused by problems in the supply of blood to the brain, typically by a series of minor strokes. Vascular dementia is the second most common form of dementia after Alzheimer's disease (AD) in older adults. Multi-infarct dementia (MID) is thought to be irreversible and it is caused by a number of small strokes or sometimes a large stroke preceded or followed by other smaller strokes. The term refers to a group of syndromes caused by different mechanisms all resulting in vascular lesions in the brain. Early detection and accurate diagnosis are important, as vascular dementia is at least partially preventable.
“Vascular Dementias Global Clinical Trials Review, H2, 2014″ provides data on the Vascular Dementias clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vascular Dementias. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Vascular Dementias. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Complete report available @ http://www.marketoptimizer.org/vascular-dementias-global-clinical-trials-review-h2-2014.html .
Scope
• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by